Related Experiment Video

Updated: Aug 7, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a

Hirokazu Takahashi1, Kouji Fujita, Toshio Fujisawa

  • 1Gastroenterology Division, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.

Cancer Science
|June 30, 2006
PubMed

Insights

PPARgamma antagonists inhibit esophageal cancer cell invasion and adherence, independent of apoptosis. This suggests PPARgamma is a potential therapeutic target for esophageal cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Esophageal cancer is aggressive and requires novel therapeutic strategies.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor found in various cancers, including esophageal cancer.
  • Understanding PPARgamma's role is crucial for developing new treatments.

Purpose of the Study:

  • To investigate the effect of PPARgamma antagonists on esophageal cancer cell invasion and growth.
  • To explore the underlying molecular mechanisms, including cell signaling pathways.
  • To determine if PPARgamma could be a viable therapeutic target for esophageal cancer.

Main Methods:

  • Treatment of esophageal cancer cell lines with PPARgamma antagonists (T0070907 and GW9662) at varying concentrations.
  • Assessment of cell invasion, adherence, growth, and apoptosis.
  • Analysis of cell morphology and key cell signaling pathways, including FAK-MAPK.

Main Results:

  • Low concentrations of PPARgamma antagonists reduced esophageal cancer cell invasion and adherence.
  • High concentrations induced growth inhibition and apoptosis, but these effects did not explain low-concentration results.
  • Inhibition of invasion at low concentrations was linked to morphological changes and altered FAK-MAPK signaling, independent of apoptosis.

Conclusions:

  • PPARgamma antagonists effectively inhibit esophageal cancer cell invasion and adherence.
  • The FAK-MAPK pathway is likely involved in PPARgamma-mediated inhibition of invasion.
  • PPARgamma represents a promising novel therapeutic target for esophageal cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...